Prostate cancer in young men: an important clinical entity

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature reviews. Urology

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrurol.2014.91PMID 24818853PMCID PMC4191828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cross-sectional and longitudinal association between hemoglobin concentration and hypertension

  2016cited by this paper
• The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland

  2013cited by this paper
• The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial.

  2013cited by this paper
• HOXB13 Mutation and Prostate Cancer: Studies of Siblings and Aggressive Disease

  2013cited by this paper
• HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk

  2013cited by this paper
• HOXB13 mutations in a population‐based, case–control study of prostate cancer

  2013cited by this paper
• Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes

  2012cited by this paper
• A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer

  2012cited by this paper
• Confirmation of the HOXB13 G84E Germline Mutation in Familial Prostate Cancer

  2012cited by this paper
• HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)

  2012cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)

  2012cited by this paper
• Recent Explosive Human Population Growth Has Resulted in an Excess of Rare Genetic Variants

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People

  2012cited by this paper
• Prostate cancer epidemiology in the United States

  2012cited by this paper
• Early onset prostate cancer has a significant genetic component

  2012cited by this paper
• SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)

  2012cited by this paper
• Germline mutations in HOXB13 and prostate-cancer risk.

  2012cited by this paper
• Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

  2012cited by this paper
• Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer

  2011cited by this paper
• An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis

  2011cited by this paper
• Treatment decision‐making for localized prostate cancer: What younger men choose and why

  2011cited by this paper
• Genetic Variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality

  2011cited by this paper
• Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.

  2011cited by this paper
• Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination

  2011cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Sedentary Behavior and Cancer: A Systematic Review of the Literature and Proposed Biological Mechanisms

  2010cited by this paper
• Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.

  2010cited by this paper
• HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling

  2010cited by this paper
• Time trends and local variation in primary treatment of localized prostate cancer.

  2010cited by this paper
• Abstract LB-435: Treatment decision-making for clinically localized Gleason score 6 prostate cancer: What younger men choose and why

  2010cited by this paper
• Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology

  2010cited by this paper
• Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.

  2010cited by this paper
• Uncovering the roles of rare variants in common disease through whole-genome sequencing

  2010cited by this paper
• Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members.

  2010cited by this paper
• Single and Multigenic Analysis of the Association between Variants in 12 Steroid Hormone Metabolism Genes and Risk of Prostate Cancer

  2009cited by this paper
• Genetic Variants and Family History Predict Prostate Cancer Similar to Prostate-Specific Antigen

  2009cited by this paper
• Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

  2009cited by this paper
• Finding the missing heritability of complex diseases

  2009cited by this paper
• Established Prostate Cancer Susceptibility Variants are not Associated with Disease Outcome

  2009cited by this paper
• Long-term outcomes in younger men following permanent prostate brachytherapy.

  2009cited by this paper
• Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

  2009cited by this paper
• Estimation of absolute risk for prostate cancer using genetic markers and family history

  2009cited by this paper
• Stage‐specific cancer incidence: An artificially mixed multinomial logit model

  2009cited by this paper
• Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality

  2009cited by this paper
• Clinical utility of five genetic variants for predicting prostate cancer risk and mortality

  2009cited by this paper
• Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer

  2009cited by this paper
• Treatment and survival outcomes in young men diagnosed with prostate cancer

  2009cited by this paper
• Prostate cancer susceptibility loci: finding the genes.

  2008cited by this paper
• Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era

  2008cited by this paper
• Chromosome 8q24 risk variants in hereditary and non‐hereditary prostate cancer patients

  2008cited by this paper
• Cumulative association of five genetic variants with prostate cancer.

  2008cited by this paper
• The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

  2008cited by this paper
• Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations

  2008cited by this paper
• Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study

  2007cited by this paper
• Impact of patient age on biochemical recurrence rates following radical prostatectomy.

  2007cited by this paper
• Why do men choose one treatment over another?

  2006cited by this paper
• Brachytherapy in men aged ≤ 54 years with clinically localized prostate cancer

  2006cited by this paper
• Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study

  2006cited by this paper
• A population model of prostate cancer incidence

  2006cited by this paper
• Outcomes for men younger than 50 years undergoing radical prostatectomy.

  2005cited by this paper
• An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data sets

  2005cited by this paper
• Effect of screening and adjuvant therapy on mortality from breast cancer

  2005cited by this paper
• The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study.

  2005cited by this paper
• National Center for Health Statistics (NCHS)

  2005cited by this paper
• Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer.

  2004cited by this paper
• Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.

  2004cited by this paper
• Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D.

  2004cited by this paper
• Is there age bias in the treatment of localized prostate carcinoma?

  2004cited by this paper
• Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma

  2003cited by this paper
• Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.

  2003cited by this paper
• Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

  2003cited by this paper
• Meta-Analysis of Measures of Sexual Activity and Prostate Cancer

  2002cited by this paper
• Effect of young age on prostate cancer survival: a population-based assessment (United States)

  2002cited by this paper
• Meta-analysis of measures of sexual activity and prostate cancer.

  2002cited by this paper
• Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

  2000cited by this paper
• Treatment decisions for localized prostate cancer

  2000cited by this paper
• Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.

  1999cited by this paper
• Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings.

  1999cited by this paper
• Genetic susceptibility to non-polyposis colorectal cancer

  1999cited by this paper
• Androgen‐independent expression of hoxb‐13 in the mouse prostate

  1999cited by this paper
• Clinical Course of Early Onset Prostate Cancer with Special Reference to Family History as a Prognostic Factor

  1998cited by this paper
• de la Chapelle, A.

  1997cited by this paper
• Radical prostatectomy in men less than 50 years old.

  1995cited by this paper
• Patient age as a prognostic factor in prostate cancer.

  1994cited by this paper
• The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer.

  1994cited by this paper
• Cancer in Poland.

  1993cited by this paper
• Mendelian inheritance of familial prostate cancer.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Prostate cancer in men less than 45 years old: influence of stage, grade and therapy.

  1987cited by this paper
• Cancer of the prostate. Do younger men have a poorer survival rate?

  1984cited by this paper
• The prognosis of prostatic cancer in the younger man.

  1983cited by this paper
• Age and survival in prostatic carcinoma.

  1983cited by this paper
• Carcinoma of prostate in men less than fifty years old. Data from American College of Surgeons' National Survey.

  1982cited by this paper
• Early age of onset in familial breast cancer. Genetic and cancer control implications.

  1976cited by this paper
• Prostatic adenocarcinoma occurring in men under 50 years of age

  1972cited by this paper
• Adenocarcinoma of the prostate in men less than 56 years old: a study of 65 cases.

  1971cited by this paper
• Cancer of the prostate in men less than 50 years old: an analysis of 51 cases.

  1969cited by this paper
• On the theory of screening for chronic diseases

  1969cited by this paper

• Influence of diabetes mellitus and anti-diabetic drugs on pathophysiology and prognosis for primary prostate cancer.

  2026cites this paper
• Global, regional, and national burden of early-onset prostate cancer, 1990-2021: a systematic analysis for the global burden of disease study 2021.

  2026cites this paper
• A high-grade undifferentiated prostate malignancy in a young male suggestive of male adnexal tumour of Wolffian origin - A rare case and diagnostic challenge.

  2026cites this paper
• Application and prospect of artificial intelligence in diagnostic imaging of prostate cancer

  2026cites this paper
• Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening

  2025cites this paper
• Global insight of early-onset genitourinary cancers in adolescents and adults from 1990 to 2021: temporal trends and health inequalities analyses

  2025cites this paper
• Psychological distress in Saudi prostate cancer patients: exploring prevalence and sociodemographic influences

  2025cites this paper
• Characteristics of Germline and Somatic Mutations of DNA Repair Genes in Korean Men with Prostate Cancer

  2025cites this paper
• The United States Preventive Services Task Force (USPSTF) Guidelines vs. Electronic Health Record (EHR)-Based Screening: A Comparative Accuracy Study in Prostate Cancer

  2025cites this paper
• Association of cigarette use with risk of prostate cancer among US males: a cross-sectional study from NHANES 1999–2020

  2025influential citation
• Treatment Landscape for Older Men With Metastatic Hormone‐Sensitive Prostate Cancer in the United States

  2025cites this paper
• Prostate Cancer Mortality in Iranian Men During 1990–2021: An Age-Period-Cohort and Joinpoint Regression Analysis

  2025cites this paper
• Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs

  2025cites this paper
• Prostate cancer in men under 50: the impact of race/ethnicity and family history

  2025cites this paper
• Exploring the Epidemiological Characteristics and Survival Analysis Among Prostate Cancer Patients Under 50: A Seer‐Based Population Study

  2025cites this paper
• Molecular Landscape of Prostate Cancer Across Age Groups: Impact on Prognosis and Treatment Outcomes

  2025influential citation
• Trends in Prostate Cancer Incidence and Survival by Gleason Score from 2000 to 2020: A Population-Based Study in Northeastern Italy

  2025cites this paper
• Lesional volume in the prediction of clinically significant prostate cancer

  2025cites this paper
• Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study.

  2025cites this paper
• Comparative Analysis of miRNA Expression 106a‐5p and 375‐3p and Proteins ERK1/2, p38, β‐Catenin and E‐Cadherin in Prostate Cancer and Benign Prostatic Hyperplasia

  2025cites this paper
• The Role of Genetic Testing in Localized Prostate Cancer.

  2025cites this paper
• Prostate Cancer Before 50: A Wake-Up Call

  2025cites this paper
• Genetic evidence for associations between food intake and prostatic diseases: a Mendelian randomization study

  2025cites this paper
• Long term outcomes of prostate cancer patients aged 55 years or younger treated with definitive radiotherapy: Trod 09-005 study

  2025cites this paper
• High-Grade Early-Onset Prostate Cancer: Assessment of TMPRSS2::ERG-Negative Tumors Suggests Low Frequency of Germline Alterations and a Pathogenic Role for HOXB13.

  2025cites this paper
• Germline DNA Repair and Immune-metabolic Alterations Suggest a Potentially Distinct Form of Early-onset Prostate Cancer in Men of African Descent.

  2025cites this paper
• Outcomes of the management of synchronous rectal and prostate cancer: a systematic review

  2025cites this paper
• Is the Incidence of Early‐Onset Adenocarcinomas in Aotearoa New Zealand Increasing?

  2025cites this paper
• Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata

  2024cites this paper
• Adipose-derived stem cells: an upcoming novel therapeutic in the management of Erectile dysfunction post radical prostatectomy in prostate cancer patients

  2024cites this paper
• An Updated Evaluation of Atrazine-Cancer Incidence Associations among Pesticide Applicators in the Agricultural Health Study Cohort

  2024cites this paper
• Epitranscriptomic mechanisms of androgen signalling and prostate cancer

  2024cites this paper
• Neuroendocrine Prostate Cancer: Report of a Prostate Cancer Subtype with Atypical Metastatic Imaging and Clinical Findings

  2024influential citation
• Exploring Prostate Cancer Incidence Trends and Age Change in Cancer Registration Areas of Jiangsu Province, China, 2009 to 2019

  2024cites this paper
• Germline variants in early and late-onset Brazilian prostate cancer patients.

  2024cites this paper
• Risk factors for early readmission to hospital in patients with malignancy-related ascites: a retrospective cohort study

  2024cites this paper
• Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics

  2024cites this paper
• Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer

  2024cites this paper
• GPCR-Gα13 Involvement in Mitochondrial Function, Oxidative Stress, and Prostate Cancer

  2024cites this paper
• Bidirectional influence between benign prostatic hyperplasia, prostate cancer, and prostatitis and mental disorders: two-sample and multivariate mendelian randomization analyses

  2024cites this paper
• Histopathological features of prostatic carcinoma in a Southwest tertiary institution in Nigeria

  2024cites this paper
• Navigating Management of Localized Prostate Cancer in the Geriatric Population.

  2024cites this paper
• Research Progress on the Association between Obesity and Prostate Cancer

  2024cites this paper
• Development of a redox-related prognostic signature for predicting biochemical-recurrence-free survival of prostate cancer

  2023cites this paper
• Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey

  2023cites this paper
• The Prevalence of Prostate Cancer Among Young Men Below 55 Years of Age in Nigeria

  2023cites this paper
• The impact of socioeconomic status on the survival of men with early-onset prostate cancer.

  2023cites this paper
• Global and regional quality of care index for prostate cancer: an analysis from the Global Burden of Disease study 1990–2019

  2023cites this paper
• Neighbourhood social deprivation and risk of prostate cancer

  2023cites this paper
• Dietary and Serum Antioxidants Associated with Prostate-Specific Antigen for Middle-Aged and Older Men

  2023cites this paper
• Molecular characteristics of Asian male BRCA-related cancers

  2023cites this paper
• Global burden of prostate cancer attributable to smoking among males in 204 countries and territories, 1990–2019

  2023cites this paper
• Investigating the racial gap in prostate cancer screening with prostate-specific antigen among younger men from 2012 to 2020

  2023cites this paper
• Long-Term Exposure to Nitrate and Trihalomethanes in Drinking Water and Prostate Cancer: A Multicase–Control Study in Spain (MCC-Spain)

  2023cites this paper
• Prognostic microRNAs as biomarkers for prostate cancer

  2023cites this paper
• Prostate cancer in workers exposed to night-shift work: two cases recognized by the Korean Epidemiologic Investigation Evaluation Committee

  2023cites this paper
• Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life.

  2023cites this paper
• Function of microRNA-124 in the pathogenesis of cancer (Review)

  2023cites this paper
• Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics

  2023cites this paper
• Defining the Population and Target Population in Clinical Studies: Clarifying Terminology and Enhancing Study Validity

  2023cites this paper
• MATCHING BRCA AND PROSTATE CANCER IN A PUBLIC HEALTH SYSTEM: REPORT OF THE ITALIAN SOCIETY FOR URO-ONCOLOGY (SIUrO) CONSENSUS PROJECT.

  2023cites this paper
• Changes in thyroid function in prostate cancer patients receiving docetaxel chemotherapy at Haji Adam Malik Hospital, Indonesia

  2023cites this paper
• Nomogram for predicting the overall survival of patients with early‐onset prostate cancer: A population‐based retrospective study

  2022cites this paper
• Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies

  2022cites this paper
• Racial disparities in treatment delay among younger men with prostate cancer

  2022cites this paper
• Survival of adult patients with solid cancer in Reunion Island, 1998-2014.

  2022cites this paper
• Retrospective Analysis of Complications from Prostate Cancer among Nigerians

  2022cites this paper
• Prostate cancers in men under the age of 50: about a series in Togo, Sub-Saharan Africa

  2022cites this paper
• Comparison of histopathological features, survival, and oncological outcome between patients under and above 55-year-old with prostate cancer who underwent radical prostatectomy

  2022cites this paper
• Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry

  2022cites this paper
• Prostate cancer mortality in Brazil 1990-2019: geographical distribution and trends

  2022cites this paper
• Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States

  2022cites this paper
• Human bone marrow mesenchymal stem cells-derived exosomes attenuated prostate cancer progression via the miR-99b-5p/IGF1R axis

  2022cites this paper
• Establishment of Prognostic Nomograms for Early-Onset Prostate Cancer Patients: A SEER Database Analysis

  2022cites this paper
• Germline Variants in DNA Damage Repair Genes and HOXB13 Among Black Patients With Early-Onset Prostate Cancer

  2022cites this paper
• Age- and Stage-Dependent Prostate Cancer Aggressiveness Associated with Differential Notch Signaling

  2022cites this paper
• Identifying intragenic functional modules of genomic variations associated with cancer phenotypes by learning representation of association networks

  2022cites this paper
• Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost‐effective?

  2022cites this paper
• Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss

  2022cites this paper
• Urinary Zinc Loss Identifies Prostate Cancer Patients

  2022cites this paper
• Early prediction of prostate cancer risk in younger men using polygenic risk scores and electronic health records

  2022cites this paper
• Germline Mutations in Patients With Early-Onset Prostate Cancer

  2022cites this paper
• Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness

  2022cites this paper
• The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches

  2022cites this paper
• Role of Genetic Variations in CDK2, CCNE1 and p27KIP1 in Prostate Cancer

  2022cites this paper
• Assessing volatile organic compounds exposure and prostate-specific antigen: National Health and Nutrition Examination Survey, 2001–2010

  2022cites this paper
• PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

  2022cites this paper
• Risikoadaptierte Früherkennung des Prostatakarzinoms – Update 2021

  2021cites this paper
• Latest Comprehensive Medical Resource Consumption in Robot-Assisted versus Laparoscopic and Traditional Open Radical Prostatectomy: A Nationwide Population-Based Cohort Study

  2021cites this paper
• Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease

  2021cites this paper
• [New recommendations for prostate cancer screening with PSA].

  2021cites this paper
• Prostate Cancer Screening and Young Black Men: Can Early Communication Avoid Later Health Disparities?

  2021cites this paper
• Case fatality rates for COVID-19 are higher than case fatality rates for motor vehicle accidents for individuals over 40 years of age

  2021cites this paper
• Impact of age on treatment response in men with prostate cancer treated with radiotherapy

  2021cites this paper
• Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers

  2021cites this paper
• Treating the patient and not just the cancer: therapeutic burden in prostate cancer

  2021cites this paper
• Ligand Based Design, ADMET and Molecular Docking Studies of Arylpiperazine Derivatives as Potent Anti-Proliferate Agents Against LNCAP Prostate Cancer Cell Lines

  2021cites this paper
• Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions

  2021cites this paper
• Comorbidity Prevalence and Impact on Quality of Life in Gay and Bisexual Men Following Prostate Cancer Treatment

  2021cites this paper
• Cáncer de próstata de inicio temprano. ¿Una nueva entidad?

  2021cites this paper